search
Back to results

Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery (OPT)

Primary Purpose

Myocardial Ischemia

Status
Terminated
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Propofol
Sevoflurane
Sponsored by
Triemli Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Myocardial Ischemia focused on measuring ischemia, cardiac surgery, volatile anesthetic, total intravenous anesthesia

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Diabetes
  • Elective cardiac surgery

Exclusion Criteria:

  • Emergency procedures
  • Preop myocardial infarction
  • Preop cardiac failure
  • Preop renal replacement therapy

Sites / Locations

  • Triemli City Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sevoflurane

Propofol

Arm Description

Volatile anesthesia for elective cardiac surgery

Total intravenous anesthesia for elective cardiac surgery

Outcomes

Primary Outcome Measures

Biomarker NT-proBNP
Difference between volatile anesthesia and total intravenous anesthesia

Secondary Outcome Measures

Receptor Substrate phosphorylization (IRS-1)/PP2A
Difference between volatile anesthesia and total intravenous anesthesia
Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)
Difference between volatile anesthesia and total intravenous anesthesia

Full Information

First Posted
March 18, 2015
Last Updated
March 8, 2018
Sponsor
Triemli Hospital
Collaborators
University of Alberta
search

1. Study Identification

Unique Protocol Identification Number
NCT02407626
Brief Title
Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery
Acronym
OPT
Official Title
Optimierung Der Kardioprotektion Durch Inhalative Anästhetika Eine Untersuchung Bei Patienten Mit Diabetes Mellitus während Off-pump Herzchirurgie
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Terminated
Why Stopped
Very low patient recruitment, changed insurance requirements
Study Start Date
September 2015 (undefined)
Primary Completion Date
March 7, 2018 (Actual)
Study Completion Date
March 7, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Triemli Hospital
Collaborators
University of Alberta

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the myocardial protection against perioperative ischemia comparing two standard anesthetic regimes in diabetic patients undergoing elective cardiac surgery. Half of the patients will receive volatile anesthesia while the other half will receive total intravenous anesthesia. Primary and secondary outcome parameters will be assessed after induction of anesthesia, at the end of the procedure and postoperative day 1 to 3.
Detailed Description
Volatile anaesthetics such as Sevoflurane have shown to have a protective effect regarding myocardial ischemia in the perioperative setting - the so-called "preconditioning". However the observed response of preconditioning in clinical trials is not consistent. An increased perioperative insulin resistance especially in diabetic patients resulting in an increased postoperative morbidity and mortality may be responsible for these findings. In an animal model, the use of propofol that is being routinely applied for general anesthesia was associated with a change of the insulin receptor substrate via phosphorylation and thus a change of insulin resistance. Avoiding a total intravenous anesthesia and applying a volatile anesthesia may result in an increased cardioprotective effect by a reduction of the perioperative insulin resistance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Ischemia
Keywords
ischemia, cardiac surgery, volatile anesthetic, total intravenous anesthesia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sevoflurane
Arm Type
Experimental
Arm Description
Volatile anesthesia for elective cardiac surgery
Arm Title
Propofol
Arm Type
Active Comparator
Arm Description
Total intravenous anesthesia for elective cardiac surgery
Intervention Type
Drug
Intervention Name(s)
Propofol
Intervention Description
Total intravenous anesthesia is a clinical standard procedure
Intervention Type
Drug
Intervention Name(s)
Sevoflurane
Intervention Description
Volatile anesthesia is a clinical standard procedure
Primary Outcome Measure Information:
Title
Biomarker NT-proBNP
Description
Difference between volatile anesthesia and total intravenous anesthesia
Time Frame
1. after induction of anesthesia 2. after chest closure 3.-5. postoperative day 1, day 2, day 3
Secondary Outcome Measure Information:
Title
Receptor Substrate phosphorylization (IRS-1)/PP2A
Description
Difference between volatile anesthesia and total intravenous anesthesia
Time Frame
1. beginning of cardiac surgery, 2. end of cardiac surgery
Title
Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)
Description
Difference between volatile anesthesia and total intravenous anesthesia
Time Frame
1. beginning of cardiac surgery, 2. end of cardiac surgery

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetes Elective cardiac surgery Exclusion Criteria: Emergency procedures Preop myocardial infarction Preop cardiac failure Preop renal replacement therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Zollinger, MD
Organizational Affiliation
Institute of Anesthesiology and Intensive Care Medicine Triemli City Hospital Zurich
Official's Role
Study Chair
Facility Information:
Facility Name
Triemli City Hospital
City
Zurich
ZIP/Postal Code
8063
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12766638
Citation
Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003 Jun;98(6):1315-27. doi: 10.1097/00000542-200306000-00004.
Results Reference
background
PubMed Identifier
17325502
Citation
Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M, Furrer L, Schaub MC, Tavakoli R, Genoni M, Zollinger A, Zaugg M. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology. 2007 Mar;106(3):444-57. doi: 10.1097/00000542-200703000-00008.
Results Reference
background
PubMed Identifier
17913754
Citation
Piriou V, Mantz J, Goldfarb G, Kitakaze M, Chiari P, Paquin S, Cornu C, Lecharny JB, Aussage P, Vicaut E, Pons A, Lehot JJ. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth. 2007 Nov;99(5):624-31. doi: 10.1093/bja/aem264. Epub 2007 Oct 3.
Results Reference
background
PubMed Identifier
14504159
Citation
Zaugg M, Lucchinetti E, Uecker M, Pasch T, Schaub MC. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth. 2003 Oct;91(4):551-65. doi: 10.1093/bja/aeg205.
Results Reference
background
PubMed Identifier
14504160
Citation
Zaugg M, Lucchinetti E, Garcia C, Pasch T, Spahn DR, Schaub MC. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth. 2003 Oct;91(4):566-76. doi: 10.1093/bja/aeg206.
Results Reference
background
PubMed Identifier
17707752
Citation
Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9. doi: 10.1016/S0140-6736(07)61296-3.
Results Reference
background
PubMed Identifier
25437926
Citation
Lou PH, Lucchinetti E, Zhang L, Affolter A, Gandhi M, Zhakupova A, Hersberger M, Hornemann T, Clanachan AS, Zaugg M. Propofol (Diprivan(R)) and Intralipid(R) exacerbate insulin resistance in type-2 diabetic hearts by impairing GLUT4 trafficking. Anesth Analg. 2015 Feb;120(2):329-40. doi: 10.1213/ANE.0000000000000558.
Results Reference
background
PubMed Identifier
21304998
Citation
Whittington RA, Virag L, Marcouiller F, Papon MA, El Khoury NB, Julien C, Morin F, Emala CW, Planel E. Propofol directly increases tau phosphorylation. PLoS One. 2011 Jan 31;6(1):e16648. doi: 10.1371/journal.pone.0016648.
Results Reference
background
PubMed Identifier
22914999
Citation
Swart MJ, De Jager WH, Kemp JT, Nel PJ, Van Staden SL, Joubert G. The effect of the metabolic syndrome on the risk and outcome of coronary artery bypass graft surgery. Cardiovasc J Afr. 2012 Aug;23(7):400-4. doi: 10.5830/CVJA-2012-055.
Results Reference
background
PubMed Identifier
20683255
Citation
Wang L, Ko KW, Lucchinetti E, Zhang L, Troxler H, Hersberger M, Omar MA, Posse de Chaves EI, Lopaschuk GD, Clanachan AS, Zaugg M. Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift. Anesthesiology. 2010 Sep;113(3):541-51. doi: 10.1097/ALN.0b013e3181e2c1a1.
Results Reference
background

Learn more about this trial

Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery

We'll reach out to this number within 24 hrs